The purpose of this study is to determine if a liquid biopsy, a method of detecting cancer from a blood draw, combined with a PET/CT scan, a type of radiological scan, is better at determining whether a lung nodule is cancerous when compared to a PET/CT scan alone. A PET/CT scan is already used for diagnosis of lung nodules, but its efficacy is uncertain in nodules 6-20 mm in size. Therefore, the PET/CT will be evaluated for its diagnostic ability in lesions this size alone and in combination with a liquid biopsy. Secondarily, a machine learning model will be created to see if the combination of the PET/CT imaging data and the liquid biopsy data can predict the presence of cancer.
Over 18 years of age ECOG performance status of 0,1, or 2
Newly discovered lung nodule with:
At least one solid lung nodule measuring 6 mm- 20 mm in greatest diameter detected on screening CT No single lesion larger than 20 mm in greatest diameter when multiple nodules present High- or intermediate-risk nodules per American College of Chest Physician (ACCP) guidelines Able to provide informed consent
Exclusion Criteria:
Prior cancer of any type for the previous 3 years Prior organ, bone marrow, of hematopoietic stem cell transplant Contraindication to administration of [18F]FDG Inability to undergo a PET/CT scan Ongoing infection, either acute or subacute Severe COPD or lung disease requiring home oxygen use Pregnancy
